Free Trial

Evoke Pharma (EVOK) Competitors

Evoke Pharma logo
$3.60 +0.16 (+4.49%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EVOK vs. JATT, MTEX, NRSN, VYNE, CVM, PASG, SNYR, GELS, LEXX, and ALVR

Should you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include JATT Acquisition (JATT), Mannatech (MTEX), NeuroSense Therapeutics (NRSN), VYNE Therapeutics (VYNE), CEL-SCI (CVM), Passage Bio (PASG), Synergy CHC Corp. (Uplisting) (SNYR), Gelteq (GELS), Lexaria Bioscience (LEXX), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry.

Evoke Pharma vs.

Evoke Pharma (NASDAQ:EVOK) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.

48.0% of JATT Acquisition shares are owned by institutional investors. 2.3% of Evoke Pharma shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

JATT Acquisition has a net margin of 0.00% compared to Evoke Pharma's net margin of -71.32%. JATT Acquisition's return on equity of -49.58% beat Evoke Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Evoke Pharma-71.32% -308.49% -53.66%
JATT Acquisition N/A -49.58%2.84%

In the previous week, Evoke Pharma had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Evoke Pharma and 0 mentions for JATT Acquisition. Evoke Pharma's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company Overall Sentiment
Evoke Pharma Neutral
JATT Acquisition Neutral

JATT Acquisition has lower revenue, but higher earnings than Evoke Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evoke Pharma$10.25M0.54-$7.79M-$2.87-1.29
JATT AcquisitionN/AN/A$6.85MN/AN/A

Evoke Pharma received 360 more outperform votes than JATT Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Evoke PharmaOutperform Votes
360
57.69%
Underperform Votes
264
42.31%
JATT AcquisitionN/AN/A

Summary

JATT Acquisition beats Evoke Pharma on 6 of the 9 factors compared between the two stocks.

Get Evoke Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVOK vs. The Competition

MetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.52M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.349.0626.7119.71
Price / Sales0.54251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book-0.406.456.774.50
Net Income-$7.79M$143.98M$3.23B$248.22M
7 Day Performance16.72%2.41%1.80%0.56%
1 Month Performance48.00%4.56%11.10%13.17%
1 Year Performance-31.63%-2.67%17.11%7.30%

Evoke Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVOK
Evoke Pharma
0.1066 of 5 stars
$3.70
+7.2%
N/A-36.3%$5.52M$10.25M-0.344Negative News
Gap Up
JATT
JATT Acquisition
N/A$1.11
-7.5%
N/A-82.1%$19.15MN/A0.003High Trading Volume
MTEX
Mannatech
1.1134 of 5 stars
$9.93
-5.9%
N/A+34.0%$18.88M$117.87M-12.26250News Coverage
Analyst Forecast
Gap Down
NRSN
NeuroSense Therapeutics
2.7009 of 5 stars
$1.37
+3.8%
$14.00
+921.9%
+19.0%$18.72MN/A-2.1410
VYNE
VYNE Therapeutics
1.9522 of 5 stars
$1.22
flat
$6.25
+412.3%
-63.0%$18.56M$605,000.00-1.4230Analyst Downgrade
Gap Up
High Trading Volume
CVM
CEL-SCI
N/A$0.20
-8.6%
N/A-88.5%$18.55MN/A-0.4243News Coverage
Gap Down
High Trading Volume
PASG
Passage Bio
2.0947 of 5 stars
$0.30
-1.3%
$7.50
+2,416.8%
-76.5%$18.52MN/A-0.25130Gap Up
SNYR
Synergy CHC Corp. (Uplisting)
2.5707 of 5 stars
$2.11
-11.3%
$10.00
+373.9%
N/A$18.47M$34.83M0.0040Trending News
Earnings Report
Analyst Revision
Gap Down
GELS
Gelteq
N/A$1.88
-1.6%
N/AN/A$17.74MN/A0.00N/APositive News
LEXX
Lexaria Bioscience
2.0166 of 5 stars
$1.00
-1.0%
$7.00
+600.0%
-67.9%$17.74M$525,923.00-2.007
ALVR
AlloVir
N/A$3.48
-1.7%
N/A-81.8%$17.55MN/A-0.17110Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:EVOK) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners